297 related articles for article (PubMed ID: 32558455)
1. [Antifibrotic therapy and progressive lung fibrosis].
Fellrath JM
Rev Med Suisse; 2020 Jun; 16(698):1256-1260. PubMed ID: 32558455
[TBL] [Abstract][Full Text] [Related]
2. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
[TBL] [Abstract][Full Text] [Related]
3. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
Gibson CD; Kugler MC; Deshwal H; Munger JS; Condos R
Lung; 2020 Aug; 198(4):597-608. PubMed ID: 32591895
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
[TBL] [Abstract][Full Text] [Related]
5. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
[TBL] [Abstract][Full Text] [Related]
6. Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis.
Collins BF; Raghu G
Eur Respir Rev; 2019 Sep; 28(153):. PubMed ID: 31578210
[TBL] [Abstract][Full Text] [Related]
7. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence.
Richeldi L; Varone F; Bergna M; de Andrade J; Falk J; Hallowell R; Jouneau S; Kondoh Y; Morrow L; Randerath W; Strek M; Tabaj G
Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578333
[TBL] [Abstract][Full Text] [Related]
9. Fibrosing interstitial lung diseases: knowns and unknowns.
Cottin V; Wollin L; Fischer A; Quaresma M; Stowasser S; Harari S
Eur Respir Rev; 2019 Mar; 28(151):. PubMed ID: 30814139
[TBL] [Abstract][Full Text] [Related]
10. Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience.
Isshiki T; Sakamoto S; Yamasaki A; Shimizu H; Miyoshi S; Nakamura Y; Homma S; Kishi K
Respir Med; 2021 Oct; 187():106551. PubMed ID: 34343721
[TBL] [Abstract][Full Text] [Related]
11. Idiopathic pulmonary fibrosis in the era of antifibrotic therapy: Searching for new opportunities grounded in evidence.
Robalo-Cordeiro C; Campos P; Carvalho L; Borba A; Clemente S; Freitas S; Furtado S; Jesus JM; Leal C; Marques A; Melo N; Souto-Moura C; Neves S; Sousa V; Santos A; Morais A
Rev Port Pneumol (2006); 2017; 23(5):287-293. PubMed ID: 28668400
[TBL] [Abstract][Full Text] [Related]
12. Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update.
Wongkarnjana A; Yanagihara T; Kolb MR
Expert Rev Respir Med; 2019 Dec; 13(12):1139-1146. PubMed ID: 31564185
[No Abstract] [Full Text] [Related]
13. Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review.
Amati F; Stainer A; Polelli V; Mantero M; Gramegna A; Blasi F; Aliberti S
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175556
[TBL] [Abstract][Full Text] [Related]
14. Developments in the management of idiopathic pulmonary fibrosis.
Drug Ther Bull; 2015 Jul; 53(7):78-81. PubMed ID: 26159700
[TBL] [Abstract][Full Text] [Related]
15. A Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone. Inhibition of Collagen Fibril Assembly.
Knüppel L; Ishikawa Y; Aichler M; Heinzelmann K; Hatz R; Behr J; Walch A; Bächinger HP; Eickelberg O; Staab-Weijnitz CA
Am J Respir Cell Mol Biol; 2017 Jul; 57(1):77-90. PubMed ID: 28257580
[TBL] [Abstract][Full Text] [Related]
16. Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
Takehara K; Koga Y; Hachisu Y; Utsugi M; Sawada Y; Saito Y; Yoshimi S; Yatomi M; Shin Y; Wakamatsu I; Umetsu K; Kouno S; Nakagawa J; Sunaga N; Maeno T; Hisada T
Cells; 2022 Jan; 11(1):. PubMed ID: 35011705
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.
Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M
Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058
[TBL] [Abstract][Full Text] [Related]
18. Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study.
Corral M; DeYoung K; Kong AM
BMC Pulm Med; 2020 Jul; 20(1):188. PubMed ID: 32652979
[TBL] [Abstract][Full Text] [Related]
19. ATP-induced fibrogenic pathway in circulating cells obtained by idiopathic pulmonary fibrotic (IPF) patients is not blocked by nintedanib and pirfenidone.
Colarusso C; Falanga A; Di Caprio S; Terlizzi M; D'Andria E; Antonio M; Maiolino P; Sorrentino R
Biomed Pharmacother; 2024 Jul; 176():116896. PubMed ID: 38876049
[TBL] [Abstract][Full Text] [Related]
20. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
Makino S
Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
